BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15512820)

  • 1. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
    Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
    Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
    Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
    Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
    Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
    Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.
    Horny HP; Sotlar K; Stellmacher F; Krokowski M; Agis H; Schwartz LB; Valent P
    J Clin Pathol; 2006 Mar; 59(3):298-302. PubMed ID: 16505282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
    Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.
    Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP
    J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
    Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
    J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
    Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
    Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.
    Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
    J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
    Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
    Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
    Valent P; Escribano L; Parwaresch RM; Schemmel V; Schwartz LB; Sotlar K; Sperr WR; Horny HP
    Int Arch Allergy Immunol; 1999 Sep; 120(1):1-7. PubMed ID: 10529583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis].
    Horny HP; Krokowski M; Feller AC; Hintze G; Sotlar K; Valent P
    Wien Klin Wochenschr; 2002 Mar; 114(5-6):222-8. PubMed ID: 12238313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).
    Horny HP; Sotlar K; Stellmacher F; Valent P; Grabbe J
    J Clin Pathol; 2006 Mar; 59(3):264-8. PubMed ID: 16505276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
    Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
    Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.